NUVB Nuvation Bio Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1811063 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY654.2%
TTM net income YoY37.5%
TTM EPS YoY20.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-61.2%
Net margin-67.4%
FCF margin—
EBITDA margin-60.1%
Returns
ROE-49.1%
ROA-19.7%
ROIC (approx.)-30.5%
Asset turnover0.29x
Leverage & solvency
Liabilities / assets70.7%
Debt / equity1.25x
Current ratio7.45x
Interest coverage-5.87x
Cash quality & payout
Operating cash flow / net income0.78x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $62.90M | $7.87M | $0 | — | — |
| Cost of revenue | — | $7.08M | $0 | — | — |
| Gross profit | — | $795,000 | $0 | — | — |
| R&D expense | $115.11M | $99.12M | $71.29M | $87.81M | $69.04M |
| SG&A expense | $151.56M | $69.23M | $28.53M | $31.92M | $24.28M |
| Operating income | -$213.06M | -$592.63M | -$99.82M | -$119.73M | -$93.32M |
| Interest expense | $13.68M | $341,000 | $0 | — | — |
| Pretax income | -$204.63M | -$567.94M | -$75.80M | -$104.20M | -$86.85M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$204.63M | -$567.94M | -$75.80M | -$104.20M | -$86.85M |
| EBITDA | -$211.32M | -$591.94M | -$99.60M | -$119.53M | -$93.13M |
| EPS (basic) | -0.60 | -2.11 | -0.35 | -0.48 | -0.44 |
| EPS (diluted) | -0.60 | -2.11 | -0.35 | -0.48 | -0.44 |
| Weighted avg. shares (diluted) | 341,541 | 268,772 | 218,880 | 216,721 | 197,887 |
| Balance sheet | |||||
| Cash & equivalents | $164.09M | $35.72M | $42.65M | $101.10M | $132.42M |
| Short-term investments | $365.12M | $466.97M | $568.56M | $559.91M | $632.97M |
| Inventory | $11.41M | $0 | — | — | — |
| Current assets | $571.52M | $526.25M | $616.43M | $667.32M | $772.07M |
| PP&E, net | $564,000 | $586,000 | $717,000 | $894,000 | $786,000 |
| Intangibles | $11.21M | $4.62M | $0 | — | — |
| Total assets | $594.82M | $540.63M | $621.48M | $672.14M | $776.15M |
| Current liabilities | $82.23M | $58.24M | $13.97M | $13.16M | $16.93M |
| Short-term debt | $5.72M | $6.28M | $0 | — | — |
| Long-term debt | $47.21M | — | — | — | — |
| Total debt | $52.93M | — | — | — | — |
| Total liabilities | $289.11M | $76.84M | $16.36M | $17.07M | $30.15M |
| Shareholders' equity | $305.72M | $463.79M | $605.12M | $655.08M | $746.00M |
| Net debt | -$111.15M | — | — | — | — |
| Shares outstanding | 346.50M | 337.84M | 219.05M | 218.63M | 217.95M |
| Cash flow statement | |||||
| Operating cash flow | -$173.43M | -$130.41M | -$68.00M | -$96.11M | -$68.19M |
| Capital expenditure | $8.00M | $0 | — | — | — |
| Free cash flow | -$181.43M | -$130.41M | — | — | — |
| Investing cash flow | $99.52M | $122.70M | $8.92M | $63.46M | -$454.67M |
| Financing cash flow | $202.53M | $331,000 | $628,000 | $1.33M | $625.53M |
| Depreciation & amortization | $1.74M | $683,000 | $222,000 | $199,000 | $184,000 |
| Stock-based compensation | $35.89M | $32.27M | $19.51M | $16.29M | $9.27M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.